Skip to content

Isobutylamido thiazolyl resorcinol for prevention of UVB-induced hyperpigmentation

Isobutylamido thiazolyl resorcinol for prevention of UVB-induced hyperpigmentation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200410001
Enrollment
Unknown
Registered
2020-04-10
Start date
2019-10-24
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of UVB induced hyperpigmentation UVB hyperpigmentation

Interventions

one side of inner arm was randomized 0.15% Isobutylamido thiazolyl resorcinol (ITR) for 3 weeks (week 0) &#45
3 hyperpigmentary spots induced by local broadband UVB was irradiated at inner arm at week 3,&#45
one side of inner arm was randomized as a control site (no cream or treatment was applied) &#45
3 hyperpigmentary spots induced by local broadband UVB was irradiated at inner arm at week 3
Experimental Drug,No Intervention No treatment
Isobutylamido thiazolyl resorcinol (ITR),none

Sponsors

Division of Dermatology, Department of medicine, Faculty of Medicine, Ramathibodi hospital
Lead Sponsor
Beiersdorf (Thailand) Company Limited
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Healthy subjects

Exclusion criteria

Exclusion criteria: -serious underlying conditions -pregnancy or breast feeding -active skin diseases on experimental sites -history of photosensitive disorders -concomitant use of topical medications -previously received laser performing on experimental sites

Design outcomes

Primary

MeasureTime frame
mean lightness index baseline, week 3, week 4, week 5, week 6, week 7 value range from 0 (total black) to 100 (total white); measured using colorimeter

Secondary

MeasureTime frame
hyperpigmentation score by blinded dermatologist baseline, week 3, week 4, week 5, week 6, week 7 evaluated by a blinded dermatologist using visual analogue scale ,hyperpigmentation score by subjects baseline, week 3, week 4, week 5, week 6, week 7 evaluated by a blinded dermatologist using visual analogue scale ,Adverse events at every visit evaluate and record by investigators

Contacts

Public ContactVasanop Vachiramon

Faculty of Medicine, Ramathibodi hospital

vasanop@gmail.com662011166

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026